Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection: The VIRAKINETICS II study

Alesia Uglietti, Giovanni Ravasi, Valeria Meroni, Pasquale Narciso, Nicoletta Ladisa, Salvatore Martini, Paolo Perini, Lucia Testa, Alessandro Masala, Lisa Malicarne, Cecilia Occhino, Elena Donadel, Francesco Genco, Guido Chichino, Renato Maserati

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Virakinetics II was designed as an observational, multicenter cohort study conducted in HIV-positive patients treated with NFV-based combinations. Trough (pre-dose) concentrations of NFV+M8 in plasma were determined using a novel ELISA test (NFV TDM-ELISA®) and analyzed using clinical and laboratory parameters. Drug levels were sorted as below, within or above a given interval (3.5 μg/mL, respectively). Longitudinal analysis was performed in a subset of patients who underwent two or more determinations. Ninety patients on NFV-containing HAART were enrolled and 43 were coinfected with HCV and/or HBV. Among coinfected patients, 10 subjects had a clinical or histological diagnosis of cirrhosis. Compared to the HIV-monoinfected, the coinfected patients were significantly older, more treatment-experienced, with higher frequency of lipodystrophy and altered liver function test values (all p values: trough concentrations were higher in coinfected patients, but without reaching statistical significance (p=0.2). This new ELISA test proved to be a rapid, convenient and reliable tool for assessing NFV+M8 plasma levels in HIV-positive patients. It could be suitable for use within the framework of routine clinical practice even in peripheral centers without specialized laboratories.

Original languageEnglish
Pages (from-to)293-301
Number of pages9
JournalCurrent HIV Research
Volume7
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Coinfection
Enzyme-Linked Immunosorbent Assay
HIV
Lipodystrophy
Liver Function Tests
Highly Active Antiretroviral Therapy
M8-nelfinavir
Multicenter Studies
Fibrosis
Cohort Studies
Pharmaceutical Preparations

Keywords

  • ELISA
  • HIV therapy
  • Nelfinavir
  • Pharmacokinetics
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection : The VIRAKINETICS II study. / Uglietti, Alesia; Ravasi, Giovanni; Meroni, Valeria; Narciso, Pasquale; Ladisa, Nicoletta; Martini, Salvatore; Perini, Paolo; Testa, Lucia; Masala, Alessandro; Malicarne, Lisa; Occhino, Cecilia; Donadel, Elena; Genco, Francesco; Chichino, Guido; Maserati, Renato.

In: Current HIV Research, Vol. 7, No. 3, 2009, p. 293-301.

Research output: Contribution to journalArticle

Uglietti, A, Ravasi, G, Meroni, V, Narciso, P, Ladisa, N, Martini, S, Perini, P, Testa, L, Masala, A, Malicarne, L, Occhino, C, Donadel, E, Genco, F, Chichino, G & Maserati, R 2009, 'Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection: The VIRAKINETICS II study', Current HIV Research, vol. 7, no. 3, pp. 293-301. https://doi.org/10.2174/157016209788347967
Uglietti, Alesia ; Ravasi, Giovanni ; Meroni, Valeria ; Narciso, Pasquale ; Ladisa, Nicoletta ; Martini, Salvatore ; Perini, Paolo ; Testa, Lucia ; Masala, Alessandro ; Malicarne, Lisa ; Occhino, Cecilia ; Donadel, Elena ; Genco, Francesco ; Chichino, Guido ; Maserati, Renato. / Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection : The VIRAKINETICS II study. In: Current HIV Research. 2009 ; Vol. 7, No. 3. pp. 293-301.
@article{71e676f1b77d44c48a3ec6c57795c96c,
title = "Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection: The VIRAKINETICS II study",
abstract = "Virakinetics II was designed as an observational, multicenter cohort study conducted in HIV-positive patients treated with NFV-based combinations. Trough (pre-dose) concentrations of NFV+M8 in plasma were determined using a novel ELISA test (NFV TDM-ELISA{\circledR}) and analyzed using clinical and laboratory parameters. Drug levels were sorted as below, within or above a given interval (3.5 μg/mL, respectively). Longitudinal analysis was performed in a subset of patients who underwent two or more determinations. Ninety patients on NFV-containing HAART were enrolled and 43 were coinfected with HCV and/or HBV. Among coinfected patients, 10 subjects had a clinical or histological diagnosis of cirrhosis. Compared to the HIV-monoinfected, the coinfected patients were significantly older, more treatment-experienced, with higher frequency of lipodystrophy and altered liver function test values (all p values: trough concentrations were higher in coinfected patients, but without reaching statistical significance (p=0.2). This new ELISA test proved to be a rapid, convenient and reliable tool for assessing NFV+M8 plasma levels in HIV-positive patients. It could be suitable for use within the framework of routine clinical practice even in peripheral centers without specialized laboratories.",
keywords = "ELISA, HIV therapy, Nelfinavir, Pharmacokinetics, Therapeutic drug monitoring",
author = "Alesia Uglietti and Giovanni Ravasi and Valeria Meroni and Pasquale Narciso and Nicoletta Ladisa and Salvatore Martini and Paolo Perini and Lucia Testa and Alessandro Masala and Lisa Malicarne and Cecilia Occhino and Elena Donadel and Francesco Genco and Guido Chichino and Renato Maserati",
year = "2009",
doi = "10.2174/157016209788347967",
language = "English",
volume = "7",
pages = "293--301",
journal = "Current HIV Research",
issn = "1570-162X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection

T2 - The VIRAKINETICS II study

AU - Uglietti, Alesia

AU - Ravasi, Giovanni

AU - Meroni, Valeria

AU - Narciso, Pasquale

AU - Ladisa, Nicoletta

AU - Martini, Salvatore

AU - Perini, Paolo

AU - Testa, Lucia

AU - Masala, Alessandro

AU - Malicarne, Lisa

AU - Occhino, Cecilia

AU - Donadel, Elena

AU - Genco, Francesco

AU - Chichino, Guido

AU - Maserati, Renato

PY - 2009

Y1 - 2009

N2 - Virakinetics II was designed as an observational, multicenter cohort study conducted in HIV-positive patients treated with NFV-based combinations. Trough (pre-dose) concentrations of NFV+M8 in plasma were determined using a novel ELISA test (NFV TDM-ELISA®) and analyzed using clinical and laboratory parameters. Drug levels were sorted as below, within or above a given interval (3.5 μg/mL, respectively). Longitudinal analysis was performed in a subset of patients who underwent two or more determinations. Ninety patients on NFV-containing HAART were enrolled and 43 were coinfected with HCV and/or HBV. Among coinfected patients, 10 subjects had a clinical or histological diagnosis of cirrhosis. Compared to the HIV-monoinfected, the coinfected patients were significantly older, more treatment-experienced, with higher frequency of lipodystrophy and altered liver function test values (all p values: trough concentrations were higher in coinfected patients, but without reaching statistical significance (p=0.2). This new ELISA test proved to be a rapid, convenient and reliable tool for assessing NFV+M8 plasma levels in HIV-positive patients. It could be suitable for use within the framework of routine clinical practice even in peripheral centers without specialized laboratories.

AB - Virakinetics II was designed as an observational, multicenter cohort study conducted in HIV-positive patients treated with NFV-based combinations. Trough (pre-dose) concentrations of NFV+M8 in plasma were determined using a novel ELISA test (NFV TDM-ELISA®) and analyzed using clinical and laboratory parameters. Drug levels were sorted as below, within or above a given interval (3.5 μg/mL, respectively). Longitudinal analysis was performed in a subset of patients who underwent two or more determinations. Ninety patients on NFV-containing HAART were enrolled and 43 were coinfected with HCV and/or HBV. Among coinfected patients, 10 subjects had a clinical or histological diagnosis of cirrhosis. Compared to the HIV-monoinfected, the coinfected patients were significantly older, more treatment-experienced, with higher frequency of lipodystrophy and altered liver function test values (all p values: trough concentrations were higher in coinfected patients, but without reaching statistical significance (p=0.2). This new ELISA test proved to be a rapid, convenient and reliable tool for assessing NFV+M8 plasma levels in HIV-positive patients. It could be suitable for use within the framework of routine clinical practice even in peripheral centers without specialized laboratories.

KW - ELISA

KW - HIV therapy

KW - Nelfinavir

KW - Pharmacokinetics

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=67649083767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649083767&partnerID=8YFLogxK

U2 - 10.2174/157016209788347967

DO - 10.2174/157016209788347967

M3 - Article

C2 - 19442125

AN - SCOPUS:67649083767

VL - 7

SP - 293

EP - 301

JO - Current HIV Research

JF - Current HIV Research

SN - 1570-162X

IS - 3

ER -